Here, we aimed to compare the cancer risk among RA patients starting TNFα blocker and those taking nonbiologic disease modifying antirheumatic drug (nbDMARD) in a large cohort of patients with RA, based on a Taiwanese nationwide database. This evidence concerns the gene TNF and rheumatoid arthritis.